X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12883) 12883
Book Review (2823) 2823
Publication (1007) 1007
Book Chapter (59) 59
Magazine Article (39) 39
Conference Proceeding (33) 33
Newsletter (23) 23
Dissertation (8) 8
Book / eBook (6) 6
Trade Publication Article (5) 5
Web Resource (5) 5
Newspaper Article (4) 4
Data Set (2) 2
Transcript (2) 2
Government Document (1) 1
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11339) 11339
index medicus (11285) 11285
antiviral agents - therapeutic use (8472) 8472
ribavirin - therapeutic use (7270) 7270
male (6306) 6306
female (6068) 6068
hepatitis c, chronic - drug therapy (5987) 5987
ribavirin (5624) 5624
middle aged (5229) 5229
interferon-alpha - therapeutic use (5047) 5047
adult (4735) 4735
drug therapy, combination (4453) 4453
hepatitis c (4373) 4373
gastroenterology & hepatology (3958) 3958
treatment outcome (3904) 3904
hepacivirus - genetics (3243) 3243
hepatitis c virus (3198) 3198
interferon (3193) 3193
polyethylene glycols - therapeutic use (2829) 2829
genotype (2802) 2802
recombinant proteins (2720) 2720
hepatitis c - drug therapy (2560) 2560
aged (2289) 2289
virus-infection (2101) 2101
hepatitis (2092) 2092
therapy (2075) 2075
plus ribavirin (2001) 2001
hepatitis c, chronic - virology (1972) 1972
infectious diseases (1966) 1966
antiviral agents - adverse effects (1963) 1963
infection (1901) 1901
hepacivirus - drug effects (1898) 1898
antiviral agents - administration & dosage (1773) 1773
ribavirin - administration & dosage (1720) 1720
health aspects (1712) 1712
virology (1710) 1710
viral load (1631) 1631
pharmacology & pharmacy (1539) 1539
care and treatment (1428) 1428
hepatitis c, chronic - complications (1412) 1412
ribavirin - adverse effects (1412) 1412
antiviral agents (1406) 1406
recombinant proteins - therapeutic use (1397) 1397
biological response modifiers (1373) 1373
rna, viral - blood (1270) 1270
interferon-alpha - adverse effects (1269) 1269
drug therapy (1259) 1259
interferons - therapeutic use (1241) 1241
sustained virological response (1212) 1212
hcv (1209) 1209
interferon-alpha - administration & dosage (1203) 1203
pegylated interferon (1128) 1128
retrospective studies (1101) 1101
abridged index medicus (1071) 1071
liver (1071) 1071
immunology (1056) 1056
analysis (1054) 1054
animals (1054) 1054
infections (1033) 1033
risk factors (1032) 1032
virus diseases (1022) 1022
combination therapy (1017) 1017
antiviral agents - pharmacology (989) 989
cirrhosis (974) 974
chronic hepatitis-c (954) 954
time factors (949) 949
viruses (904) 904
antiviral therapy (865) 865
genetic aspects (865) 865
hepacivirus - isolation & purification (858) 858
hepatitis c - complications (855) 855
adolescent (846) 846
chronic hepatitis c (845) 845
virus (845) 845
recurrence (836) 836
young adult (834) 834
hiv infections - complications (832) 832
peginterferon alpha-2a (831) 831
medicine, general & internal (815) 815
prospective studies (798) 798
combination (790) 790
peginterferon (788) 788
microbiology (767) 767
hepatitis c - virology (764) 764
sofosbuvir (760) 760
gastroenterology and hepatology (752) 752
hepatitis c, chronic - genetics (745) 745
initial treatment (734) 734
interferon-alpha (732) 732
research (725) 725
transplantation (713) 713
patients (703) 703
polyethylene glycols - administration & dosage (696) 696
hiv (695) 695
polyethylene glycols - adverse effects (690) 690
rna (685) 685
liver transplantation (683) 683
hepatocellular-carcinoma (675) 675
telaprevir (672) 672
hiv infections - drug therapy (662) 662
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12068) 12068
Spanish (189) 189
French (184) 184
German (104) 104
Chinese (101) 101
Russian (84) 84
Japanese (66) 66
Polish (48) 48
Hungarian (41) 41
Korean (26) 26
Italian (24) 24
Portuguese (15) 15
Dutch (10) 10
Czech (6) 6
Danish (6) 6
Croatian (5) 5
Finnish (5) 5
Hebrew (5) 5
Turkish (5) 5
Serbian (4) 4
Swedish (3) 3
Norwegian (2) 2
Icelandic (1) 1
Lithuanian (1) 1
Romanian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 03/2015, Volume 162, Issue 6, pp. 407 - 419
Journal Article
Hepatology, ISSN 0270-9139, 03/2012, Volume 55, Issue 3, pp. 742 - 748
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2011, Volume 121, Issue 1, pp. 308 - 317
Chronic infection with hepatitis C virus (HCV) is a major public health problem, with nearly 170 million infected individuals worldwide Current treatment for... 
MEDICINE, RESEARCH & EXPERIMENTAL | LIVER INFLAMMATION | GAMMA-INDUCIBLE PROTEIN-10 | VIRUS-INFECTION | DIPEPTIDYL-PEPTIDASE-IV | ANTIVIRAL THERAPY | INSULIN-RESISTANCE | IMMUNE-RESPONSES | CHRONIC HEPATITIS-C | LEVELS CORRELATE | PEGINTERFERON PLUS RIBAVIRIN | Chemokine CXCL10 - blood | Prognosis | Antiviral Agents - therapeutic use | Receptors, CXCR3 - blood | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Chemokine CXCL10 - antagonists & inhibitors | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Hepatitis C, Chronic - therapy | Recombinant Proteins | Hepatitis C, Chronic - blood | Polyethylene Glycols - therapeutic use | T-Lymphocytes - virology | Treatment Failure | Hepatitis C, Chronic - immunology | Peptide Fragments - blood | Protein Array Analysis | T-Lymphocytes - immunology | Proteases | Physiological aspects | Research | Diagnosis | Hepatitis C | Drug therapy | Chemokines | Index Medicus | Abridged Index Medicus | Hepatitis C, Chronic/therapy | T-Lymphocytes/immunology | Polyethylene Glycols/therapeutic use | Dipeptidyl Peptidase 4/blood | Receptors, CXCR3/blood | Chemokine CXCL10/blood | T-Lymphocytes/virology | Hepatitis C, Chronic/blood | Interferon-alpha/therapeutic use | Chemokine CXCL10/antagonists & inhibitors | Life Sciences | Immunology | Antiviral Agents/therapeutic use | Hepatitis C, Chronic/immunology | Peptide Fragments/blood | Ribavirin/therapeutic use | Hepatitis C, Chronic/virology
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
Journal Article